Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: The Dodgy Ticker who wrote (1929)	1/26/2002 6:30:54 PM
From: Miljenko Zuanic	Respond to of 2515

Bob, C225 is very different from what PPHM/OXGN are trying to do. <<Is there a better candidate in your opinion? >> This is discussed several times here at SI, so I will just repeat. So far results for Iressa (Zeneca, filed NDA) and Tarceva (OSIP) (both are more active in monotherapy regime) indicate that they are better candidate. Also ABX-EGFr (ABGX) seems more potent (lower dose) than C225. In addition there are several candidates at early clinical (Pfizer, Novartis, Pharmacia,..) whish claim more selectivity toward EGF receptors. In addition, several new fundamental research works point that sub-specific EGF receptor(s) as target may be more desired (more specificity in receptor locations and abundance), lower side effects with higher doses. Other thinks that combination (EGFr + other from some class, heterodimerization) will bring better results. Race is far from over. I am not up to date in this field (I am not following sector with some intensity as I did in 97/98/99), so may miss something or have wrong view. Bottom line is that BMY did have very high hope for C225. Did they miss something or were misled by IMCL? Time will tell? But, I will not bet that they were as stupid as today news experts interpret. Miljenko PS: AACR meeting is good place to do research for new staff. Title: American Association for Cancer Research 93rd Annual Meeting Date: April 06, 2002 - April 10, 2002 City: San Francisco